Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Health professional cultural competence reduces the psychological and behavioral impact of negative healthcare encounters.

Flynn PM, Betancourt H, Emerson ND, Nunez EI, Nance CM.

Cultur Divers Ethnic Minor Psychol. 2019 Nov 7. doi: 10.1037/cdp0000295. [Epub ahead of print]

PMID:
31697099
2.

The TCU Drug Screen 5: Identifying Justice-involved Individuals with Substance Use Disorders.

Knight DK, Blue TR, Flynn PM, Knight K.

J Offender Rehabil. 2018;57(8):525-537. doi: 10.1080/10509674.2018.1549180. Epub 2019 Feb 5.

PMID:
31666789
3.

Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men.

Le CN, Britto P, Brummel SS, Hoffman RM, Li JZ, Flynn PM, Taha TE, Coletti A, Fowler MG, Bosch RJ, Gandhi RT, Klingman KL, McIntyre JA, Currier JS.

AIDS. 2019 Nov 15;33(14):2149-2156. doi: 10.1097/QAD.0000000000002334.

PMID:
31373919
4.

Response to correspondence entitled: Perinatal HIV and response to vaccination.

Flynn PM, Abrams EJ.

AIDS. 2019 Aug 1;33(10):1675-1677. doi: 10.1097/QAD.0000000000002247. No abstract available.

PMID:
31305335
5.

The role of physical and psychological health problems in the drug use treatment process.

Joe GW, Lehman WEK, Rowan GA, Knight K, Flynn PM.

J Subst Abuse Treat. 2019 Jul;102:23-32. doi: 10.1016/j.jsat.2019.03.011. Epub 2019 Mar 30.

PMID:
31202285
6.

Obstructive Sleep Apnea Knowledge: Attitudes and screening practices of Minnesota dental hygienists.

Reibel YG, Pusalavidyasagar S, Flynn PM.

J Dent Hyg. 2019 Jun;93(3):29-36.

PMID:
31182566
7.

Treatment Retention Satisfaction, and Therapeutic Progress for Justice-Involved Individuals Referred to Community-Based Medication-Assisted Treatment.

Yang Y, Gray J, Joe GW, Flynn PM, Knight K.

Subst Use Misuse. 2019;54(9):1461-1474. doi: 10.1080/10826084.2019.1586949. Epub 2019 Apr 29.

PMID:
31030611
8.

Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women.

Murnane PM, Bacchetti P, Currier JS, Brummel S, Okochi H, Phung N, Louie A, Kuncze K, Hoffman RM, Nematadzira T, Soko DK, Owor M, Saidi F, Flynn PM, Fowler MG, Gandhi M.

AIDS. 2019 Aug 1;33(10):1657-1662. doi: 10.1097/QAD.0000000000002237.

PMID:
31021852
9.

Antiretroviral Adherence Following Prison Release in a Randomized Trial of the imPACT Intervention to Maintain Suppression of HIV Viremia.

DiPrete BL, Pence BW, Golin CE, Knight K, Flynn PM, Carda-Auten J, Groves JS, Powers KA, White BL, Napravnik S, Wohl DA.

AIDS Behav. 2019 Sep;23(9):2386-2395. doi: 10.1007/s10461-019-02488-7.

PMID:
30963321
10.

Optimizing Drug-Drug Interaction Alerts Using a Multidimensional Approach.

Daniels CC, Burlison JD, Baker DK, Robertson J, Sablauer A, Flynn PM, Campbell PK, Hoffman JM.

Pediatrics. 2019 Mar;143(3). pii: e20174111. doi: 10.1542/peds.2017-4111. Epub 2019 Feb 13.

PMID:
30760508
11.

Confirmation of the unidimensional structure of the Oral Health Literacy Adults Questionnaire.

Flynn PM, John MT, Sistani MMN.

Int Dent J. 2019 Jun;69(3):207-213. doi: 10.1111/idj.12451. Epub 2018 Dec 7.

PMID:
30525199
12.

Drug Use Mediates the Relationship Between Depressive Symptoms and Adherence to ART Among Recently Incarcerated People Living with HIV.

Hill LM, Golin CE, Gottfredson NC, Pence BW, DiPrete B, Carda-Auten J, Groves JS, Napravnik S, Wohl D, Knight K, Flynn PM.

AIDS Behav. 2019 Aug;23(8):2037-2047. doi: 10.1007/s10461-018-2355-3.

PMID:
30535731
13.

Growing up with perinatal HIV.

Flynn PM, Abrams EJ.

AIDS. 2019 Mar 15;33(4):597-603. doi: 10.1097/QAD.0000000000002092.

PMID:
30531318
14.

Ethanol lock therapy.

Wolf J, Connell TG, Curtis N, Flynn PM.

Lancet Infect Dis. 2018 Dec;18(12):1306. doi: 10.1016/S1473-3099(18)30678-9. No abstract available.

PMID:
30507448
15.

Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations.

Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, Springer SA.

Drug Alcohol Depend. 2019 Jan 1;194:59-68. doi: 10.1016/j.drugalcdep.2018.10.003. Epub 2018 Oct 23.

PMID:
30412898
16.

Advance Care Planning and HIV Symptoms in Adolescence.

Lyon ME, Garvie PA, D'Angelo LJ, Dallas RH, Briggs L, Flynn PM, Garcia A, Cheng YI, Wang J; Adolescent Palliative Care Consortium.

Pediatrics. 2018 Nov;142(5). pii: e20173869. doi: 10.1542/peds.2017-3869. Epub 2018 Oct 19.

17.

Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial.

Wolf J, Connell TG, Allison KJ, Tang L, Richardson J, Branum K, Borello E, Rubnitz JE, Gaur AH, Hakim H, Su Y, Federico SM, Mechinaud F, Hayden RT, Monagle P, Worth LJ, Curtis N, Flynn PM.

Lancet Infect Dis. 2018 Aug;18(8):854-863. doi: 10.1016/S1473-3099(18)30224-X. Epub 2018 Jun 5.

PMID:
29884572
18.

A broader look at adolescents with perinatal HIV.

Flynn PM.

Nature. 2018 Apr;556(7702):439-440. doi: 10.1038/d41586-018-04476-8. No abstract available.

PMID:
29686368
19.

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.

Turkova A, Moore CL, Butler K, Compagnucci A, Saïdi Y, Musiime V, Nanduudu A, Kaudha E, Cressey TR, Chalermpantmetagul S, Scott K, Harper L, Montero S, Riault Y, Bunupuradah T, Volokha A, Flynn PM, Bologna R, Ramos Amador JT, Welch SB, Nastouli E, Klein N, Giaquinto C, Ford D, Babiker A, Gibb DM; BREATHER (PENTA 16) trial Group.

PLoS One. 2018 Apr 23;13(4):e0196239. doi: 10.1371/journal.pone.0196239. eCollection 2018.

20.

A model for rigorously applying the Exploration, Preparation, Implementation, Sustainment (EPIS) framework in the design and measurement of a large scale collaborative multi-site study.

Becan JE, Bartkowski JP, Knight DK, Wiley TRA, DiClemente R, Ducharme L, Welsh WN, Bowser D, McCollister K, Hiller M, Spaulding AC, Flynn PM, Swartzendruber A, Dickson MF, Fisher JH, Aarons GA.

Health Justice. 2018 Apr 13;6(1):9. doi: 10.1186/s40352-018-0068-3.

21.

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial.

Arenas-Pinto A, Grund B, Sharma S, Martinez E, Cummins N, Fox J, Klingman KL, Sedlacek D, Collins S, Flynn PM, Chasanov WM, Kedem E, Katlama C, Sierra-Madero J, Afonso C, Brouwers P, Cooper DA; INSIGHT START study group.

Clin Infect Dis. 2018 Jul 18;67(3):420-429. doi: 10.1093/cid/ciy051.

22.

Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial.

Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Gnanashanmugam D, Chakhtoura N, McCarthy K, Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga BT, Masenya M, Nyati M, Theron G, Mulenga H, Butler K, Shapiro DE; PROMISE Study Team.

J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):383-392. doi: 10.1097/QAI.0000000000001612.

23.

Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.

Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris DR, Price G, Baker A, Meyer WA 3rd, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team.

Clin Infect Dis. 2018 Jan 6;66(2):220-228. doi: 10.1093/cid/cix753.

24.

Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.

Wolf J, Tang L, Flynn PM, Pui CH, Gaur AH, Sun Y, Inaba H, Stewart T, Hayden RT, Hakim H, Jeha S.

Clin Infect Dis. 2017 Nov 13;65(11):1790-1798. doi: 10.1093/cid/cix644.

25.

Reply.

Wohl DA, Golin CE, Napravnik S, Knight K, Flynn PM.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e21-e22. doi: 10.1097/QAI.0000000000001457. No abstract available.

26.

Lessons Learned From the Implementation of Seek, Test, Treat, Retain Interventions Using Mobile Phones and Text Messaging to Improve Engagement in HIV Care for Vulnerable Populations in the United States.

Christopoulos KA, Cunningham WE, Beckwith CG, Kuo I, Golin CE, Knight K, Flynn PM, Spaulding AC, Coffin LS, Kruszka B, Kurth A, Young JD, Mannheimer S, Crane HM, Kahana SY.

AIDS Behav. 2017 Nov;21(11):3182-3193. doi: 10.1007/s10461-017-1804-8.

27.

Psychometric properties of the English version of the Oral Health Literacy Adults Questionnaire - OHL-AQ.

Flynn PM, John MT, Naik A, Kohli N, VanWormer JJ, Self K.

Community Dent Health. 2016 Dec;33(4):274-280. doi: 10.1922/CDH_3868Flynn07.

PMID:
28537364
28.

Cohort profile: seek, test, treat and retain United States criminal justice cohort.

Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM.

Subst Abuse Treat Prev Policy. 2017 May 16;12(1):24. doi: 10.1186/s13011-017-0107-4.

29.

A randomized clinical trial of adolescents with HIV/AIDS: pediatric advance care planning.

Lyon ME, D'Angelo LJ, Dallas RH, Hinds PS, Garvie PA, Wilkins ML, Garcia A, Briggs L, Flynn PM, Rana SR, Cheng YI, Wang J.

AIDS Care. 2017 Oct;29(10):1287-1296. doi: 10.1080/09540121.2017.1308463. Epub 2017 Mar 30.

30.

A structural model of treatment program and individual counselor leadership in innovation transfer.

Joe GW, Becan JE, Knight DK, Flynn PM.

BMC Health Serv Res. 2017 Mar 23;17(1):230. doi: 10.1186/s12913-017-2170-y.

31.

Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia After Prison Release: The imPACT Trial.

Wohl DA, Golin CE, Knight K, Gould M, Carda-Auten J, Groves JS, Napravnik S, Cole SR, White BL, Fogel C, Rosen DL, Mugavaro MJ, Pence BW, Flynn PM.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):81-90. doi: 10.1097/QAI.0000000000001337.

32.
33.

Pharmacotherapies as standalone treatments for addictions: why lessening won't work.

Flynn PM.

Addiction. 2017 Aug;112(8):1337-1338. doi: 10.1111/add.13707. Epub 2017 Jan 25. No abstract available.

PMID:
28124510
34.

Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.

Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team.

Clin Infect Dis. 2017 Feb 1;64(3):317-325. doi: 10.1093/cid/ciw765. Epub 2016 Nov 15.

35.

Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.

Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, McIntyre J, Gnanashanmugam D, Siberry GK, Coletti AS, Taha TE, Klingman KL, Martinson FE, Owor M, Violari A, Moodley D, Theron GB, Bhosale R, Bobat R, Chi BH, Strehlau R, Mlay P, Loftis AJ, Browning R, Fenton T, Purdue L, Basar M, Shapiro DE, Mofenson LM; IMPAACT 1077BF/1077FF PROMISE Study Team.

N Engl J Med. 2016 Nov 3;375(18):1726-1737.

36.

Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics.

Lombaard J, Bunupuradah T, Flynn PM, Ramapuram J, Ssali F, Crauwels H, Hoogstoel A, Van Eygen V, Stevens M.

Pediatr Infect Dis J. 2016 Nov;35(11):1215-1221.

PMID:
27294305
37.

Individuals motivated to participate in adherence, care and treatment (imPACT): development of a multi-component intervention to help HIV-infected recently incarcerated individuals link and adhere to HIV care.

Golin CE, Knight K, Carda-Auten J, Gould M, Groves J, L White B, Bradley-Bull S, Amola K, Fray N, Rosen DL, Mugavaro MJ, Pence BW, Flynn PM, Wohl D.

BMC Public Health. 2016 Sep 6;16:935. doi: 10.1186/s12889-016-3511-1.

38.

Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection.

Hakim H, Allison KJ, Van de Velde LA, Tang L, Sun Y, Flynn PM, McCullers JA.

Vaccine. 2016 Jun 8;34(27):3141-3148. doi: 10.1016/j.vaccine.2016.04.053. Epub 2016 Apr 26.

39.

Matching Treatment to Rhetoric - A Challenge to Policy and Programming.

Flynn PM, Brown BS.

J Subst Abuse Treat. 2016 May;64:1-2. doi: 10.1016/j.jsat.2015.06.025. Epub 2015 Dec 8. No abstract available.

40.

Catheter-Related Complications in Children With Cancer Receiving Parenteral Nutrition: Change in Risk Is Moderated by Catheter Type.

Shenep MA, Tanner MR, Sun Y, Culley T, Hayden RT, Flynn PM, Tang L, Wolf J.

JPEN J Parenter Enteral Nutr. 2017 Aug;41(6):1063-1071. doi: 10.1177/0148607115624087. Epub 2016 Jan 7.

41.

The Effectiveness of the Treatment Readiness and Induction Program (TRIP) for Improving During-Treatment Outcomes.

Knight DK, Joe GW, Crawley RD, Becan JE, Dansereau DF, Flynn PM.

J Subst Abuse Treat. 2016 Mar;62:20-7. doi: 10.1016/j.jsat.2015.11.007. Epub 2015 Nov 26.

42.

Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia.

Hakim H, Dallas R, Zhou Y, Pei D, Cheng C, Flynn PM, Pui CH, Jeha S.

Cancer. 2016 Mar 1;122(5):798-805. doi: 10.1002/cncr.29833. Epub 2015 Dec 23.

43.

Predictors of Physical Altercation among Adolescents in Residential Substance Abuse Treatment.

Crawley RD, Becan JE, Knight DK, Joe GW, Flynn PM.

Deviant Behav. 2015;36(12):996-1018. Epub 2015 Oct 29.

44.

Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins.

Sealy RE, Jones BG, Surman SL, Branum K, Howlett NM, Flynn PM, Hurwitz JL.

Viral Immunol. 2016 Jan-Feb;29(1):64-70. doi: 10.1089/vim.2015.0078. Epub 2015 Nov 6.

45.

To Stay or Not To Stay: Adolescent Client, Parent, and Counselor Perspectives on Leaving Substance Abuse Treatment Early.

Landrum B, Knight DK, Becan JE, Flynn PM.

J Child Adolesc Subst Abuse. 2015;24(6):344-354. Epub 2015 Jun 15.

46.

Infections Caused by Rapidly Growing Mycobacteria spp in Children and Adolescents With Cancer.

Apiwattankul N, Flynn PM, Hayden RT, Adderson EE.

J Pediatric Infect Dis Soc. 2015 Jun;4(2):104-13. doi: 10.1093/jpids/piu038. Epub 2014 May 7. Review.

47.

Monitoring Central Venous Catheter Resistance to Predict Imminent Occlusion: A Prospective Pilot Study.

Wolf J, Tang L, Rubnitz JE, Brennan RC, Shook DR, Stokes DC, Monagle P, Curtis N, Worth LJ, Allison K, Sun Y, Flynn PM.

PLoS One. 2015 Aug 31;10(8):e0135904. doi: 10.1371/journal.pone.0135904. eCollection 2015.

48.

The Impact of Vaccine Concerns on Racial/Ethnic Disparities in Influenza Vaccine Uptake Among Health Care Workers.

Ojha RP, Stallings-Smith S, Flynn PM, Adderson EE, Offutt-Powell TN, Gaur AH.

Am J Public Health. 2015 Sep;105(9):e35-41. doi: 10.2105/AJPH.2015.302736. Epub 2015 Jul 16.

49.

Cultural beliefs about health professionals and perceived empathy influence continuity of cancer screening following a negative encounter.

Amador JA, Flynn PM, Betancourt H.

J Behav Med. 2015 Oct;38(5):798-808. doi: 10.1007/s10865-015-9646-1. Epub 2015 Jun 2.

PMID:
26032574
50.

Dietary Adherence, Glycemic Control, and Psychological Factors Associated with Binge Eating Among Indigenous and Non-Indigenous Chileans with Type 2 Diabetes.

Herbozo S, Flynn PM, Stevens SD, Betancourt H.

Int J Behav Med. 2015 Dec;22(6):792-8. doi: 10.1007/s12529-015-9478-y.

PMID:
25786595

Supplemental Content

Loading ...
Support Center